Envisia Therapeutics
Stage
DivestitureTotal Raised
$46.1MInvestors Count
5Deal Terms
3Portfolio Exits
1Funding, Valuation & Revenue
3 Fundings
Envisia Therapeutics has raised $46.1M over 3 rounds.
Envisia Therapeutics's latest funding round was a Series A - II for $16.5M on March 17, 2016.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
3/17/2016 | Series A - II | $16.5M | Canaan Partners, and NEA | 4 | ||
10/19/2015 | Convertible Note | |||||
11/12/2013 | Series A |
Date | 3/17/2016 | 10/19/2015 | 11/12/2013 |
|---|---|---|---|
Round | Series A - II | Convertible Note | Series A |
Amount | $16.5M | ||
Investors | Canaan Partners, and NEA | ||
Valuation | |||
Revenue | |||
Sources | 4 |
Envisia Therapeutics Deal Terms
3 Deal Terms
Envisia Therapeutics's deal structure is available for 3 funding rounds, including their Series A - II from March 17, 2016.
Round | Series A - II | Convertible Note | Series A |
|---|---|---|---|
Funding Date | |||
Pre-Money Valuation | |||
Post-Money Valuation | |||
Amount Raised | |||
Shares Authorized | |||
Issuance Price | |||
Dividend Rate | |||
Liquidation Preferences | |||
Liquidation Price | |||
Participation | |||
Conversion Price | |||
Anti Dilution | |||
General Voting | |||
Board Voting | |||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Series A - II | |||||||||||||||
Convertible Note | |||||||||||||||
Series A |
Envisia Therapeutics Investors
5 Investors
Envisia Therapeutics has 5 investors. NEA invested in Envisia Therapeutics's Series A - II funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
11/12/2013 | 3/17/2016 | 2 Series A, Series A - II (2016) | Venture Capital | California | ||
Venture Capital | Connecticut | |||||
Venture Capital | North Carolina | |||||
Venture Capital | North Carolina | |||||
Venture Capital | Massachusetts |
First funding | 11/12/2013 | ||||
|---|---|---|---|---|---|
Last Funding | 3/17/2016 | ||||
Investor | |||||
Rounds | 2 Series A, Series A - II (2016) | ||||
Board Seats | |||||
Type | Venture Capital | Venture Capital | Venture Capital | Venture Capital | Venture Capital |
Location | California | Connecticut | North Carolina | North Carolina | Massachusetts |
Envisia Therapeutics Portfolio Exits
1 Portfolio Exit
Envisia Therapeutics has 1 portfolio exit. Their latest portfolio exit was Envisia Therapeutics - Drug Deliver Assets on October 05, 2017.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
10/5/2017 | Divestiture | Envisia Therapeutics - Drug Deliver Assets | 1 |
Date | 10/5/2017 |
|---|---|
Exit | Divestiture |
Companies | Envisia Therapeutics - Drug Deliver Assets |
Valuation | |
Acquirer | |
Sources | 1 |
Loading...